What it is
This is one vial holding two peptides: 10 milligrams of Tesamorelin and 3 milligrams of Ipamorelin.
Both make your body release more of its own growth hormone — the hormone that drives repair, muscle building, and fat burning — but by different routes.
Tesamorelin is a stabilised copy of growth hormone-releasing hormone, the natural signal your brain sends to the pituitary gland (a pea-sized gland at the base of the brain) telling it to release growth hormone.
Ipamorelin copies ghrelin, the hunger hormone, and attaches to the ghrelin receptor. It also raises growth hormone, and it does so without meaningfully affecting cortisol (the stress hormone) or prolactin.
Because the two work on different pathways, together they produce more growth hormone than either alone.
This blend is fussier to prepare than most. It will gel if you mix it with water alone, so it needs a small amount of acetic acid solution first. Once mixed it lasts only two weeks, and unlike most peptides it is stored at room temperature rather than in the fridge.
This entry covers dosing and preparation only — no benefits, side effects, or contraindications have been documented for the blend itself. See the individual Tesamorelin and Ipamorelin pages for those.
A fixed co-formulation of a stabilised GHRH analogue and a selective GHRP: 10 mg Tesamorelin plus 3 mg Ipamorelin, 13 mg of total peptide per vial.
Tesamorelin acts at the GHRH receptor on anterior pituitary somatotrophs; Ipamorelin at GHS-R1a, where it also suppresses somatostatin tone with minimal impact on cortisol, prolactin, acetylcholine, or aldosterone. Two arms of the same axis, so combined GH output exceeds either component alone.
The unusual ratio — roughly 3.3:1 in favour of Tesamorelin — weights the blend toward Tesamorelin's visceral-fat indication rather than toward a balanced GHRH/GHRP pairing.
Formulation notes are load-bearing here. Acetic acid solution (0.6%) is mandatory, not optional: without it the product gels. Hospira-brand bacteriostatic water is preferred for pH consistency — off-spec pH can neutralise the peptide's charge and cause aggregation, and extreme pH can denature it outright. Post-reconstitution the blend is stored at room temperature, not refrigerated, and expires in two weeks.
No benefits, side-effect, or contraindication list has been established for the blend itself. Consult the individual Tesamorelin and Ipamorelin entries.
What it does
No effects have been documented for this blend as a product. What follows comes from what each of the two peptides does on its own.
Tesamorelin's best-known effect is reducing deep abdominal fat, the kind that sits around the organs rather than under the skin. Ipamorelin's is a clean rise in growth hormone that supports lean muscle, fat burning, repair, and deeper sleep.
The pairing therefore aims at body composition — losing fat while keeping or building muscle — with the recovery and sleep benefits that come with raised growth hormone.
Read the individual Tesamorelin and Ipamorelin pages for the full detail on each.
No blend-specific pharmacology has been documented; the following is inferred from the components and is flagged as such.
Tesamorelin's characterised effect is reduction of visceral adipose tissue via sustained GHRH-receptor stimulation and the resulting GH/IGF-1 rise. Ipamorelin contributes selective GHS-R1a agonism: pulsatile GH release, lean mass accrual, lipolysis, collagen and tissue repair, and increased slow-wave sleep, without the cortisol, prolactin, acetylcholine, or aldosterone effects of less selective GHRPs.
The combination is a two-arm somatotropic stimulus weighted toward Tesamorelin, with the expected profile being visceral fat reduction plus lean mass preservation and recovery. Bedtime dosing superimposes the stimulus on the slow-wave-sleep pulse.
See the individual Tesamorelin and Ipamorelin entries for the substantiated per-component detail.
Benefits
Evidence grades: what the labels mean
- Human trials Supported by randomised or placebo-controlled human trials.
- Limited human data Some human evidence, such as pilot studies, case reports or observational data, but no controlled trials.
- Animal or lab only Shown in animal or cell studies only; not yet tested in people.
- Anecdotal No published studies; based on user reports or theory.
Each grade reflects the strongest published support for that specific claim, not for the compound as a whole.
- No benefits have been documented for this blend as a product — only dosing and preparation.Anecdotal
- Tesamorelin's established use is reducing deep abdominal fat around the organs; see the Tesamorelin page.Human trials
- Ipamorelin supports lean muscle, fat burning, tissue repair, bone density, and deeper sleep; see the Ipamorelin page.Anecdotal
- The practical reason for combining them is that two different pathways into the growth hormone system produce a bigger release than either one alone.Limited human data
- No blend-specific benefits list has been established; only dosing and reconstitution are documented.Anecdotal
- Component: Tesamorelin — visceral adipose tissue reduction via sustained GHRH-receptor stimulation.Human trials
- Component: Ipamorelin — selective GHS-R1a agonism giving pulsatile GH release, lean mass, lipolysis, collagen synthesis, bone density, and increased slow-wave sleep.Anecdotal
- Rationale for the pairing: GHRH-receptor stimulation raises pulse amplitude while GHS-R1a agonism suppresses somatostatin tone, so combined output exceeds either arm alone.Limited human data
Reconstitution and dosing
This blend takes more care to prepare than most.
Store the vial in the fridge before mixing. When you are ready, take it out and let it come to room temperature first. The acetic acid solution and the bacteriostatic water should be at room temperature too.
Mix in two steps. First add 0.5 mL (milliliters) of 0.6% acetic acid solution and let the powder dissolve. Only then add 2.5 mL of bacteriostatic water. The acetic acid is not optional — it is what stops the product turning to gel. That gives 3 mL of liquid in the vial in total, which is 300 units on an insulin syringe.
Hospira-brand bacteriostatic water is preferred because its acidity is consistent batch to batch. If the water is too acidic or too alkaline, the peptides can lose their electrical charge and clump together; a large difference can change the peptide's structure and stop it working.
After mixing, store it at room temperature — do not refrigerate it — and use it within two weeks.
Inject just under the skin, at night, at least 90 minutes after your last meal.
A cycle runs 12 to 16 weeks with a 4 to 8 week break. Each week is 5 days of dosing in a row followed by 2 rest days. Short cycles do not work: do not start this planning to try it for three or four weeks.
Weeks 1 to 6 are 23 units once a day. From week 7 you either stay at 23 units for the rest of the cycle, or step up to 46 units.
Because the vial holds 13 milligrams of peptide in 3 mL, 23 units works out to roughly 1 milligram of blend, of which about 0.77 mg is Tesamorelin and 0.23 mg is Ipamorelin.
Reconstitution is two-stage and order-dependent: 0.5 mL of 0.6% acetic acid solution first, until fully dissolved, then 2.5 mL bacteriostatic water. Total in-vial volume 3 mL (300 units), giving 4.33 mg/mL of combined peptide — 43.3 mcg of blend per insulin unit, of which 33.3 mcg is Tesamorelin and 10 mcg Ipamorelin.
The acetic acid step is mandatory; the product gels without it. Hospira-brand bacteriostatic water is preferred for pH consistency — off-spec pH neutralises the peptide charge and drives aggregation, and extreme pH denatures.
Storage: refrigerated pre-reconstitution; bring vial and both diluents to room temperature before mixing; store at room temperature post-reconstitution — explicitly do not refrigerate. Post-reconstitution expiry is 2 weeks, which at 23 units/day and 5 days/week consumes roughly 2.3 mL of the 3 mL — plan vial sizing around the expiry, not around the volume.
Subcutaneous injection, at night, at least 90 minutes post-prandial.
Cycle 12–16 weeks with a 4–8 week washout, 5 consecutive dosing days then 2 rest days. Sub-cycle trials of 3-4 weeks will not produce results.
Weeks 1-6: 23 units nightly. Weeks 7-12: either hold at 23 units or escalate to 46 units for the remainder.
Dose arithmetic: the mcg values here are back-calculated from the unit figures at 13 mg in 3 mL and reproduce 23 and 46 units exactly — 996.67 mcg and 1,993.33 mcg of total blend, i.e. approximately 767/230 mcg and 1,533/460 mcg of Tesamorelin/Ipamorelin respectively.
Tesamorelin 10 mg + Ipamorelin 3 mg vial
Reconstitute in two stages: add 0.5 mL (50 units) of 0.6% acetic acid solution first and let the powder fully dissolve, then add 2.5 mL (250 units) of bacteriostatic water — 3 mL total in the vial. The acetic acid step is mandatory; the product gels without it.
4.33 mg/mL · 43.33 mcg per unit
Cycle: 12–16 weeks, then a 4–8 week washout; shorter cycles will not produce results · Frequency: 1×/day at bedtime, at least 90 minutes after the last meal; 5 consecutive dosing days then 2 rest days
| When | Dose | Draw | How often |
|---|---|---|---|
| Weeks 1–6 — 23 units of total blend | 996.67 mcg | 23 units | 1×/day at bedtime |
| Weeks 7–12, option A — hold at 23 units | 996.67 mcg | 23 units | 1×/day at bedtime |
| Weeks 7–12, option B — increase to 46 units | 1.99 mg | 46 units | 1×/day at bedtime |
13 mg of blend in 3 mL is 4.33 mg/mL, or 43.33 mcg per unit. Draw 23 units (0.23 mL) for 996.67 mcg of blend.
- Tesamorelin766.67 mcg
- Ipamorelin230 mcg
Who should avoid it
- No contraindications have been documented for this blend at all. That is an absence of information, not evidence of safety.
- Check the individual Tesamorelin and Ipamorelin pages, and treat the cautions listed there as applying to this blend.
- Included here as reasoning from what the two components are: both are growth hormone peptides, and growth hormone peptides are generally avoided in active cancer, in pregnancy and breastfeeding, and where diabetes is uncontrolled.
- No blend-specific contraindication list has been established — only dosing and reconstitution are documented. Absence of a list is not a safety claim.
- Apply the contraindications of the components: see the Tesamorelin and Ipamorelin entries.
- The class-level cautions for GH secretagogues apply — active malignancy, pregnancy and lactation, uncontrolled diabetes or severe insulin resistance, untreated hypothyroidism, intracranial or pituitary lesions, and severe cardiovascular disease.
Side effects
- No side effects have been documented for this blend as a product.
- See the individual Tesamorelin and Ipamorelin pages for their documented side effects, and expect both sets to be possible here.
- Included here as what is commonly reported across growth hormone peptides generally: a reaction where you inject, water retention, joint aches, headache, and increased hunger.
- No blend-specific side-effect list has been established.
- Refer to the Tesamorelin and Ipamorelin entries; both component profiles should be assumed to apply.
- Class-typical effects across GH secretagogues: injection site reactions, fluid retention, arthralgia, headache, increased appetite, and reduced insulin sensitivity.
User reports
User reports are individual experiences submitted by site visitors. They are not medical advice, are not verified for accuracy, and do not reflect Amino Reference's views. Read the evidence section above and talk to a clinician. Full disclaimer.
Stacking
One of the two peptides in this vial, sold on its own. Use the standalone version if you want to set the two doses independently instead of at this fixed ratio.
One component of this blend. The standalone permits independent titration of the GHRH arm, which the fixed 10:3 ratio does not.
The other peptide in this vial, sold on its own.
The other component, and the minority one here at 3 mg against 10 mg — if the GHRP arm is what you want to push, the standalone is the better instrument.
A common partner for growth hormone peptides when there is tissue to repair, though no stacks have been specifically suggested for this blend.
No stacks have been specifically suggested for this blend. Included on the strength of the component pages: BPC-157 upregulates GH receptor expression in tendon fibroblasts, complementing raised circulating GH.
Dosing figures have been reviewed and units are recomputed from the stated protocol.